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Abstract
Aims/hypothesis There is substantial evidence that mito-
chondrial dysfunction is linked to insulin resistance and is
present in several tissues relevant to the pathogenesis of
type 2 diabetes. Here, we examined whether common
variation in genes involved in oxidative phosphorylation
(OxPhos) contributes to type 2 diabetes susceptibility or
influences diabetes-related metabolic traits.
Methods OxPhos gene variants (n=10) that had been
nominally associated (p<0.01) with type 2 diabetes in a
recent genome-wide meta-analysis (n=10,108) were selected
for follow-up in 3,599 type 2 diabetic and 4,956 glucose-
tolerant Danish individuals. A meta-analysis of these variants
was performed in 11,729 type 2 diabetic patients and 43,943
non-diabetic individuals. The impact on OGTT-derived
metabolic traits was evaluated in 5,869 treatment-naive
individuals from the Danish Inter99 study.
Results The minor alleles of COX10 rs9915302 (p=0.02)
and COX5B rs1466100 (p=0.005) showed nominal
association with type 2 diabetes in our Danish cohort.
However, in the meta-analysis, none of the investigated
variants showed a robust association with type 2 diabetes
after correction for multiple testing. Among the alleles
potentially associated with type 2 diabetes, none negatively
influenced surrogate markers of insulin sensitivity in
non-diabetic participants, while the minor alleles of
UQCRC1 rs2228561 and COX10 rs10521253 showed a
weak (p<0.01 to p<0.05) negative influence on indices of
glucose-stimulated insulin secretion.
Conclusions/interpretation We cannot rule out the possibility
that common variants in or near OxPhos genes may
influence beta cell function in non-diabetic individuals.
However, our quantitative trait studies and a sufficiently
large meta-analysis indicate that common variation in
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proximity to the examined OxPhos genes is not a major
cause of insulin resistance or type 2 diabetes.
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Type 2 diabetes is a heterogeneous disease caused by a
complex interplay between numerous genetic, epigenetic
and environmental factors. Insulin resistance in skeletal
muscle, adipose tissue and liver, together with failure of the
pancreatic beta cells to compensate for this abnormality,
plays a major role in the pathogenesis of type 2 diabetes.
Skeletal muscle, which accounts for the majority of insulin-
stimulated glucose uptake, is a major site of insulin
resistance in type 2 diabetic and high-risk individuals [1].
Numerous investigations have demonstrated that skeletal
muscle of insulin-resistant individuals shows decreased
insulin action on glucose transport and glycogen synthesis,
accumulation of lipid metabolites and impaired insulin
signalling through proximal effector proteins and glycogen
synthase [1–6]. Recent studies have provided strong
evidence of a link between insulin resistance and
mitochondrial dysfunction in human skeletal muscle [7].
Global approaches such as transcriptional profiling and
proteomics have demonstrated a co-ordinated downregu-
lation of mRNA levels and protein content of nuclear-
encoded genes involved in oxidative phosphorylation
(OxPhos) in muscle of patients with type 2 diabetes and
of high-risk individuals [8–11]. Moreover, a reduced
content and impaired functional capacity of muscle
mitochondria may also contribute to mitochondrial dys-
function in type 2 diabetes and obesity [12–14]. It has
been proposed that mitochondrial dysfunction contributes
to insulin resistance in skeletal muscle by causing an
accumulation of lipid metabolites, which in turn may
impair insulin signalling to glucose transport and glyco-
gen synthesis [7, 15]. Evidence of mitochondrial dys-
function in other tissues relevant to the pathogenesis of
type 2 diabetes is also emerging. This includes reports of
reduced expression of electron transport chain (ETC)
genes in adipose tissue of women with type 2 diabetes
[16], and of impaired mitochondrial respiratory capacity
in heart muscle [17] and liver from type 2 diabetic
individuals [18]. Finally, mitochondrial ATP production is
known to play a critical regulatory role in glucose-
stimulated insulin secretion, and several recent studies
have suggested that defects in mitochondrial OxPhos
could contribute to beta cell dysfunction in patients with
type 2 diabetes [19–22].
Taken together, these findings support the hypothesis
that mitochondrial dysfunction could be a unifying
defect in the pathogenesis of type 2 diabetes [15].
However, it remains to be established whether mitochon-
drial dysfunction is a cause or consequence of insulin
resistance and/or beta cell dysfunction in type 2 diabetes.
To date, genome-wide association (GWA) studies have
shown 38 common genetic variants to be robustly
associated with type 2 diabetes, with 16 additional loci
associated with traits of glucose homeostasis [23].
Together, they explain approximately 10% of type 2
diabetes heritability. Most of these risk alleles are located
in genes believed to influence beta cell function [23],
while only a few variants seem to be associated with
insulin resistance, e.g. a variant upstream of IRS1 [24].
Moreover, none of the above risk variants includes
common variants in OxPhos genes. However, some
studies have reported associations of a few specific
variants in OxPhos genes (NDUFB6, COX7A1 and
ATP5O) with certain phenotypical characteristics of type 2
diabetes and obesity [25–27].
Based on the accumulating evidence of mitochondrial
dysfunction in tissues relevant to the pathogenesis of type 2
diabetes, the present study was performed to examine
whether common variants in the nuclear-encoded genes,
comprising the respiratory complexes I to V and related
OxPhos genes, are associated with type 2 diabetes. Data
from a genome-wide meta-analysis were explored [28] to
select common OxPhos gene variants for follow-up in an
independent cohort of Danish individuals. We also
investigated the potential association of these genetic
variants with well-defined quantitative traits of insulin
sensitivity and beta cell function in a large Danish
cohort of individuals without diabetes.
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Methods
Gene and single-nucleotide polymorphism selection We
investigated the potential association between common
variants in 100 nuclear-encoded OxPhos genes, representing
the five respiratory complexes and related OxPhos proteins
[29], and type 2 diabetes (Electronic supplementary material
[ESM] Table 1). First, we explored the results from a meta-
analysis of data from three GWA studies of 4,539 type 2
diabetic cases and 5,569 controls published by the Diabetes
Genetics Replication and Meta-analysis (DIAGRAM) con-
sortium [28] (www.well.ox.ac.uk/DIAGRAM/, accessed
1 July 2009). We found 2,542 imputed and genotyped single-
nucleotide polymorphisms (SNPs) within or near 90 OxPhos
genes (defined as boundary of coding region ±10 kb)
(Fig. 1). For further evaluation, we then selected all 39
SNPs in the eight genes that showed nominal associa-
tion (p<0.01) with type 2 diabetes in the DIAGRAM
study (ESM Table 2). When SNPs in high linkage
disequilibrium (r2>0.8) in HapMap (Version Data Release
21a/phase II Jan07; www.hapmap.org, accessed 1 July
2009) were excluded, 11 SNPs in seven genes were found
to cover all variation and were selected for genotyping in
an independent replication cohort. We successfully geno-
typed ten SNPs in or near six OxPhos genes (NDUFV3,
UQCRC1, COX4I1, COX5B, COX6B1 and COX10) in
9,745 Danish individuals. All further analyses are based
on the evaluation of these SNPs (ESM Table 3).
Study population The case–control replication study of
Danish individuals (n=3,599 cases, n=4,956 controls)
included all unrelated type 2 diabetic patients (n=328) and
glucose-tolerant controls (n=4,444) from the Inter99 Study
sample (ClinicalTrials.gov ID: NCT00289237) [30, 31], as
well as type 2 diabetic patients (n=1,577) from the Danish
part of the Anglo–Danish–Dutch Study of Intensive Treat-
ment In PeOple With screeN Detected Diabetes in Primary
Care (ADDITION) intervention study (ClinicalTrials.gov ID:
NCT00237549) [32] and individuals recruited from the
outpatient clinic at Steno Diabetes Center (Gentofte,
Denmark) (n=1,694 cases, n=512 controls). Normal
glucose tolerance and type 2 diabetes were defined according
to World Health Organization 1999 criteria [33]. All type 2
diabetic patients were diagnosed by two independent plasma
glucose measurements. Clinical characteristics of the three
study groups and a brief description of the Inter99 and
ADDITION studies are given in ESM Study Population and
ESM Table 4. Participants of the Inter99 Study were
investigated by an OGTT with measurements of plasma
glucose and serum insulin at fasting, and at 30 and 120 min
after glucose intake as described [34]. Analyses of these
biochemical variables were used for studies of quantitative
diabetes-related traits in 5,869 treatment-naive participants
from the Inter99 cohort, excluding patients with previously
diagnosed diabetes. Informed written consent was obtained
from all participants before participation. The studies were
approved by the local ethics committees of Copenhagen and
Aarhus Counties and were conducted in accordance with the
Helsinki Declaration II.
Derived estimates of insulin release and insulin sensitivity
from an OGTT Indices of oral glucose-stimulated insulin
100 nuclear-encoded genes involved in OxPhos
39 SNPs in 8 genes
2,542 SNPs in 90 genes
Tagging in HaploView
10 SNPs in 6 genes
Association with T2D in DIAGRAM (p<0.01)
Position ±10 kb in DIAGRAM data/R 
Genotyping by KASPar allelic  
28 SNPs in high LDb
1 SNP failed to be genotypedc
2,503 SNPs with p≥0.01 
10 genes with no SNPs in DIAGRAMa
Fig. 1 Flowchart of the gene and SNP selection process. SNPs in or
near 100 nuclear-encoded candidate genes involved in OxPhos were
explored for potential association with type 2 diabetes (T2D) in the
DIAGRAM study [28]. Eleven tag-SNPs in seven genes covered all
variation in 39 SNPs showing nominal association with type 2
diabetes (p<0.01). Ten SNPs in six genes were successfully
genotyped for follow-up in a cohort of Danish individuals. aFor ten
nuclear-encoded genes no SNPs were imputed or genotyped in
DIAGRAM. bThe COX15 SNP was in linkage disequilibrium (LD)
with several of the COX10 SNPs. cThe SDHA rs3756718 SNP failed
to be genotyped and was excluded from further analysis
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secretion are reported as: (1) the insulinogenic index,
calculated as (serum insulin30min− serum insulin0min
[pmol/l])/(plasma glucose30min [mmol/l]); (2) the corrected
insulin response (CIR), calculated as (100×serum
insulin30min [pmol/l])/(plasma glucose30min [mmol/l]×
[plasma glucose30min−3.89]); and (3) the BIGTT acute
insulin response (AIR) index. The surrogate measures of
insulin sensitivity are reported as: (1) the HOMA of insulin
resistance (HOMA-IR), calculated as (plasma glucose0 min
[mmol/l]×serum insulin0 min [pmol/l])/22.5 [35]; (2) insulin
sensitivity index (ISI), calculated as the reciprocal of
HOMA-IR; and (3) the BIGTT sensitivity index (SI). The
BIGTT indices, which apply information on sex and
BMI, combined with plasma glucose and serum insulin
during an OGTT, were calculated as reported [36]. Beta
cell function was also assessed as the disposition index
(DI), i.e. insulin secretion adjusted for insulin sensitivity
by multiplying CIR and ISI, since these measures are not
intrinsically interdependent.
Biochemical and anthropometrical measures Body weight
and height were measured in light indoor clothing and
without shoes. Blood samples were drawn after a 12 h
overnight fast. Serum insulin levels were measured by a kit
(AutoDELFIA; Perkin-Elmer, Wallac, Turku, Finland).
Plasma glucose was measured using a glucose oxidase
method (Granutest; Merck, Darmstadt, Germany).
Genotyping Genotyping of the ten genetic variants was
performed using an allelic discrimination method (KASPar;
Kbioscience, Hoddeston, UK). Success rates for all variants
were above 96%. Error rates were below 0.5%. The minor
allele frequencies (MAFs) were between 0.016 and 0.497.
All ten selected SNPs obeyed Hardy–Weinberg equilibrium
(p>0.05).
Statistical analysis In our case–control replication study of
3,599 patients with type 2 diabetes and 4,956 glucose-
tolerant controls, logistic regression with adjustment for
age, sex and BMI assuming an additive model was applied
to examine differences in genotype distributions between
affected and unaffected participants. The quantitative trait
analyses were performed in the Inter99 Study involving
5,869 treatment-naive participants and applying an additive
general linear model adjusted for sex, age and BMI. All
statistical analyses were performed using RGui version
2.9.0 (available at www.r-project.org/). A value of p<0.05
was considered statistically significant for nominal
association. A meta-analysis of the selected ten SNPs
in or near six OxPhos genes was also performed in a
fixed-effect, inverse variance-weighted analysis combining
ORs and 95% CIs from our replication study of Danish
individuals and results from a recent genome-wide
meta-analysis combining data from eight studies pub-
lished by the DIAGRAM consortium, hereafter desig-
nated DIAGRAM+ [37]. It should be noted that the
selection and genotyping of OxPhos SNPs in the Danish
individuals were performed before publication of
DIAGRAM+, and that the results from the latter are not
publicly available. Homogeneity between studies was
evaluated by I2 and Q test statistics. The meta-analyses
were performed in R applying the ‘meta’ package and
using an additive model. In the meta-analysis and
quantitative trait analysis, p values below a Bonferroni-
corrected (ten SNPs) threshold of 0.05/10=0.005 were
considered statistically significant.
Power calculations In the selection of SNPs for genotyping
based on DIAGRAM results (4,539 type 2 diabetic cases,
5,569 controls), we had more than 80% statistical power to
identify a SNP with an MAF of 40% and OR of 1.1, and a
SNP with an MAF of 5% and an OR of 1.25 at a
significance level of 0.01. Statistical power in case–control
meta-analysis of the 11,729 type 2 diabetic patients and
43,943 non-diabetic individuals was calculated by simu-
lations. The power calculations assumed a Bonferroni-
adjusted alpha-value of 0.05/10=0.005 and a disease
prevalence of 8%. Given the MAFs for the ten investigated
variants (0.016 to 0.497), the meta-analysis had 80%
statistical power to detect an OR of 1.05 in a case–control
design for the most common variants (MAF 50%), whereas
we had 80% power to detect an OR of 1.20 for the lower
frequency variants (MAF 1.6%). Statistical power in studies
of quantitative traits in the 5,869 Inter99 participants was
estimated by simulations as described [34], showing that
we had 80% statistical power to detect an effect equal to
0.27 SDs in the event of an MAF of 1.6% and an effect
equal to 0.067 SDs for SNPs with an MAF of 50%. In
Inter99, this is equal to allelic differences in fasting plasma
glucose of 0.22 and 0.055 mmol/l, respectively.
Results
To find common variants in OxPhos genes potentially
associated with type 2 diabetes, we examined data from a
genome-wide meta-analysis published online by the
DIAGRAM consortium [28]. A total of 39 SNPs in eight
genes showed nominal associations (p<0.01) with type 2
diabetes (Fig. 1, ESM Table 2). Interestingly, 35 of these
SNPs were found in or near genes representing cyto-
chrome c oxidase (COX), i.e. complex IV of the ETC,
including COX4I1, COX5B, COX6B1, COX10 and
COX15. Of 25 SNPs localised to COX10, 21 showed a
stronger nominal association (p<0.001) with type 2
diabetes than any of the 14 SNPs in the other genes. We
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found that 11 SNPs in seven genes covered all variation
and selected them for follow-up in an independent cohort.
We successfully genotyped ten SNPs in or near six
OxPhos genes and examined them for association with type 2
diabetes in a case–control replication study of Danish
individuals. In a model adjusted for age, sex and BMI, the
nominal association with type 2 diabetes was replicated for the
minor G allele ofCOX10 rs9915302 (OR 1.14 [95% CI 1.02,
1.28]; p=0.020) (Table 1). In addition, the minor T allele of
COX5B rs1466100 was nominally associated with type 2
diabetes (OR 1.62 [95% CI 1.16, 2.28]; p=0.0052) in our
Danish case–control study. This is in contrast to the
DIAGRAM Study [28], where the major A allele of
rs1466100 showed nominal association with type 2
diabetes (ESM Table 2). None of the other eight SNPs
showed association with type 2 diabetes in our Danish
replication study.
To increase statistical power, we were granted access to
the results of the most recent meta-analysis reported by the
DIAGRAM consortium [37], and performed a meta-analysis
combining data from our Danish study with data from
DIAGRAM+. This increased the total sample size to 11,729
type 2 diabetic patients and 43,943 non-diabetic individuals.
In this meta-analysis, six of the ten SNPs showed nominal
association with type 2 diabetes (Table 2), including the
minor alleles of UQCRC1 rs2228561 (OR 1.08 [95% CI
1.02, 1.14]; p=0.012), COX5B rs11904110 (OR 1.08 [95%
CI 1.00, 1.16]; p=0.041), COX6B1 rs2267584 (OR 0.94
[95% CI 0.91, 0.98]; p=0.0060), COX10 rs10775377 (OR
1.05 [95% CI 1.01, 1.09]; p=0.0080), COX10 rs8077302
(OR 0.96 [95% CI 0.93, 1.00]; p=0.048) and COX10
rs9915302 (OR 1.07 [95% CI 1.02, 1.12]; p=0.0068). A
test of homogeneity revealed heterogeneity for COX5B
rs1466100 (I2=89.2%, p=0.0023); for the other nine SNPs
there was no significant heterogeneity between the study
groups (p>0.05). After adjusting for multiple testing,
none of the ten SNPs was significantly associated with
type 2 diabetes.
The ten SNPs found to be nominally associated with type 2
diabetes in the DIAGRAM Study [28] were investigated for
potential association with quantitative diabetes-related traits in
5,869 non-diabetic participants of the population-based
Inter99 cohort (ESM Tables 5–14). The minor A allele of
UQCRC1 rs2228561 showed nominal association with
decreased BIGTT-AIR (β=−0.03, p=0.04), but also with
increased BIGTT-SI (β=0.32%, p=0.0074), indicating a
negative effect on glucose-stimulated insulin secretion and a
positive effect on insulin sensitivity. The minor G allele of
COX10 rs10521253 was nominally associated with higher
plasma glucose at 30 min after an OGTT (β=0.02%,
p=0.027) and with decreased values of several indices of
beta cell function, including the insulinogenic index
(β=−0.05%, p=0.046), CIR (β=−0.07%, p=0.011), BIGTT-
AIR (β=−0.04%, p=0.028) and DI (β=−0.05%, p=0.022).
The minor A allele of COX10 rs8077302 showed nominal
association with lower fasting serum insulin (β=−0.02%,
p=0.049), and borderline associations with decreased
HOMA-IR (β=−0.02%, p=0.054) and increased ISI
(β=0.02%, p=0.054), all indicating a potential positive effect
on insulin sensitivity. Carriers of the minor C allele of
COX4I1 rs16939766 had lower serum insulin 120 min after
an OGTT (β=−0.06%, p=0.036), and carriers of the minor
T allele in NDUFV3 rs8134542 showed lower plasma glucose
120 min after an OGTT (β=−0.01%, p=0.024), both
Table 1 Association between common variants in or near OxPhos genes and type 2 diabetes in case–control analysis of 3,599 Danish type 2
diabetic cases and 4,956 glucose-tolerant controls
Gene Zygosity type 2 diabetes Zygosity controls Values
Gene SNP Allelesa MAF Wild-type Heterozygous Homozygous Wild-type Heterozygous Homozygous OR (95% CI) p valueb
COX5B rs11904110 T/C 0.058 3,071 403 13 4,309 550 18 1.16 (0.96, 1.40) 0.11
COX5B rs1466100 A/T 0.016 3,367 130 2 4,719 144 2 1.62 (1.16, 2.28) 0.0052
UQCRC1 rs2228561 C/T 0.13 2,600 828 65 3,661 1,103 78 1.12 (0.98, 1.28) 0.084
COX4I1 rs16939766 G/C 0.054 3,112 381 9 4,354 494 17 1.08 (0.89, 1.3) 0.44
COX10 rs10775377 A/C 0.41 1,189 1,688 618 1,727 2,307 817 1.07 (0.98, 1.17) 0.14
COX10 rs10521253 A/G 0.069 3,033 439 10 4,220 609 18 1.01 (0.84, 1.17) 0.94
COX10 rs8077302 G/A 0.50 890 1,756 845 1,232 2,394 1,240 0.99 (0.91, 1.08) 0.88
COX10 rs9915302 T/G 0.19 2,218 1,131 140 3,238 1,423 166 1.14 (1.02, 1.28) 0.020
COX6B1 rs2267584 G/A 0.32 1,657 1,507 346 2,226 2,114 522 0.93 (0.85, 1.02) 0.13
NDUFV3 rs8134542 C/T 0.24 2,004 1,294 202 2,775 1,782 297 0.98 (0.89, 1.09) 0.75
Effect of genotype was calculated for the minor allele of each SNP
aMajor/minor allele
b Calculated assuming an additive model with adjustment for sex, age and BMI
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indicating improved glucose homeostasis. The remaining five
SNPs showed no nominal associations with any of the
investigated quantitative diabetes-related traits (data not
shown). After adjustment for multiple testing none of the
observed nominal associations remained significant.
Discussion
Based on the substantial evidence that mitochondrial
dysfunction is linked to insulin resistance and beta cell
dysfunction, and is present in multiple tissues relevant to
the pathogenesis of type 2 diabetes [7–22], we hypothesised
that common variation in OxPhos genes contributes to an
increased risk of type 2 diabetes or influences metabolic
traits related to the disease. OxPhos gene variants showing
nominal association with type 2 diabetes in a meta-analysis
of three GWA studies that were part of the DIAGRAM
Study [28] were selected for follow-up in an independent
cohort of Danish individuals. In our Danish cohort, we
replicated the nominal association of the minor G allele of
COX10 rs9915302 with type 2 diabetes, while finding that
the minor T allele of COX5B rs1466100, rather than the
major A allele, was nominally associated with type 2
diabetes. Combining the genotyping results from our
Danish cohort with those from DIAGRAM+ [37], sample
size was increased to 11,729 type 2 diabetic cases and
43,943 controls. In this meta-analysis, none of the
investigated OxPhos gene variants showed robust associa-
tion with type 2 diabetes after correction for multiple
testing. Moreover, quantitative traits analysis showed only
nominally significant associations between five SNPs and
different metabolic traits of glucose homeostasis, such as a
weak negative effect of the minor alleles of UQCRC1
rs2228561 and COX10 rs10521253 on indices of glucose-
stimulated insulin secretion. Taken together, these data
show no robust association between common variation in
OxPhos genes and type 2 diabetes. Moreover, although we
cannot completely rule out the possibility that some SNPs
in or near OxPhos genes may contribute to impaired
glucose-stimulated insulin secretion, our results provide
evidence that the major role played by insulin resistance in
the pathogenesis of type 2 diabetes cannot be explained by
such genetic variants.
The hypothesis of a potential association between
common variation in OxPhos genes and type 2 diabetes
was strongly supported a priori by numerous metabolic and
physiological studies [7–18]. This makes our study unique
compared with replication studies and meta-analysis of
previously identified type 2 diabetes risk alleles, for most of
which knowledge of the underlying phenotype leading to
type 2 diabetes is limited [23]. The present study is, to our
knowledge, the first to replicate a nominal association
between OxPhos gene variants and type 2 diabetes. Its
major strength, however, is that in a sufficiently large meta-
analysis of 11,729 type 2 diabetic cases and 43,943
controls, we provide evidence that common variation in
OxPhos genes does not robustly contribute to the risk of
type 2 diabetes. Consistently, our analysis of quantitative
metabolic traits in a Danish non-diabetic cohort demonstrated
that among the OxPhos alleles showing nominal association
with type 2 diabetes in the DIAGRAM study [28],
none negatively influenced surrogate markers of insulin
sensitivity. These results support recent observations in
insulin receptor-deficient individuals showing that mito-
chondrial dysfunction in skeletal muscle is probably the
consequence rather than the cause of insulin resistance in
common forms of type 2 diabetes [38]. Thus in
individuals with a heterozygous mutation in the tyrosine
kinase domain of INSR, which is known to cause insulin
resistance via impaired insulin signalling [39], a measure
of skeletal muscle mitochondrial function in vivo was
significantly reduced [38].
In our quantitative metabolic traits analysis, we observed
a nominal significant negative influence of the minor alleles
of UQCRC1 rs2228561 and COX10 rs10521253 on indices
of glucose-stimulated insulin secretion. Correspondingly, a
recent study showed two other common variants in or near
OxPhos genes to be nominally associated with a decreased
insulinogenic index [40]. In this study of Olsson et al. [40],
variants in or near 76 nuclear-encoded OxPhos genes were
explored for potential association with type 2 diabetes and
insulinogenic index in the Diabetes Genetic Initiative (DGI)
GWA Study [41]. In contrast to our study, the investigators
were unable to find any variants nominally associated with
type 2 diabetes, probably because the DGI study cohort size
Table 2 Meta-analysis of association between common variants in or
near OxPhos genes and type 2 diabetes in 11,729 type 2 diabetic cases
and 43,943 non-diabetic controls
Gene SNP MAF OR (95% CI) p value
COX5B rs11904110 0.058 1.08 (1.00, 1.16) 0.041
COX5B rs1466100 0.016 1.01 (0.87, 1.17) 0.91
UQCRC1 rs2228561 0.13 1.08 (1.02, 1.14) 0.012
COX4I1 rs16939766 0.054 1.05 (0.97, 1.14) 0.25
COX10 rs10775377 0.41 1.05 (1.01, 1.09) 0.0080
COX10 rs10521253 0.069 0.97 (0.91, 1.04) 0.41
COX10 rs8077302 0.50 0.96 (0.93, 1.00) 0.048
COX10 rs9915302 0.19 1.07 (1.02, 1.12) 0.0068
COX6B1 rs2267584 0.32 0.94 (0.91, 0.98) 0.0060
NDUFV3 rs8134542 0.24 1.02 (0.98, 1.07) 0.30
Combined effects and p values were calculated by a fixed-effect meta-
analysis applying an additive genetic model
Effect of genotype was calculated for the minor allele of each SNP
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was only one third of the DIAGRAM cohort size [28]. On
the other hand, Olsson et al. found nine SNPs in or near
OxPhos genes showing nominal association (p<0.01) with
the insulinogenic index in 1,467 non-diabetic participants
of the DGI study [40]. The top two of these SNPs,
rs606164 adjacent to NDUFC2 and rs1323070 adjacent to
COX7A2, were genotyped and nominal association repli-
cated in a larger cohort of 4,323 non-diabetic participants
from the PPP-Botnia study [40]. Because no SNPs in or
near NDUFC2 or COX7A2 showed nominal association
with type 2 diabetes in the DIAGRAM study [28], they
were not genotyped for quantitative trait analysis in our
5,869 non-diabetic individuals. The study of Olsson et al.
[40] provides evidence that some common variants in or
near OxPhos genes may increase susceptibility to impaired
beta cell function in non-diabetic individuals, even when
the same OxPhos variants show no association with type 2
diabetes. Although this possibility is not supported by a
very recent large-scale study of the combined effect of
several OxPhos variants [42], we cannot rule out the
possibility that additional OxPhos gene variants among
those genotyped in the DIAGRAM study [28] would have
shown association with indices of beta cell secretion in our
Danish cohort.
Among the OxPhos gene variants nominally associated
with type 2 diabetes in the DIAGRAM study [28], most
(~90%) were found in or near nuclear-encoded genes
(COX4I1, COX5B, COX6B1, COX10, COX15) involved in
the regulation or assembly of COX, complex IV of the
ETC. More than 70% of these COX-related SNPs were
localised to COX10, and common variation in COX10 was
covered by genotyping four COX10 SNPs. The nominal
association of the minor G allele of COX10 rs9915302 with
type 2 diabetes was replicated in our Danish case–control
cohort, and the minor allele of COX10 rs10521253 showed
nominal association with several indices of impaired beta
cell function, including BIGTT-AIR, CIR, DI and insulino-
genic index. The COX10 gene encodes a COX assembly
protein involved in the mitochondrial haem biosynthetic
pathway, and is one of six nuclear genes in which mutations
cause isolated COX deficiency [43]. Although none of the
examined COX-related SNPs showed robust association
with type 2 diabetes, the observed enrichment of COX10
SNPs among variants nominally associated with type 2
diabetes suggests that sequencing of low-frequency variants
in or near COX10, for example, could lead to the discovery
of SNPs with a higher impact on indices of beta cell
function and type 2 diabetes risk.
A potential limitation of the present study is that, based
on the available evidence from in vivo studies of human
skeletal muscle and beta cell islets, we decided to focus
selectively on nuclear-encoded OxPhos genes. That is, we
did not include transcriptional regulators of mitochondrial
genes or any other of the ~1,000 genes encoding
proteins proposed to reside and function within mito-
chondria [44]. Thus common variation in genes involved,
for example, in citric acid cycle, beta-oxidation, reactive
oxygen species (ROS) production and apoptosis were not
studied. Moreover, we only investigated nuclear-encoded
OxPhos genes, excluding any variation in the 13 OxPhos
genes known to be encoded by mitochondrial DNA.
However, it was recently demonstrated that common
variation in genes encoded by mitochondrial DNA is not
associated with type 2 diabetes or related metabolic traits
[45]. Another limitation of the present study is that the
studies of quantitative metabolic traits related to type 2
diabetes were based on OGTT-derived measures of
insulin secretion and insulin sensitivity, rather than the
application of gold-standard methods. A recent report
indicates that, in particular, caution is required when
interpreting differences in OGTT-derived values of insu-
lin sensitivity, because such differences may reflect
variations in beta cell function, rather than true variations
in insulin sensitivity [46]. Moreover, we did not test
whether the combined effect of all genotyped SNPs in or
near OxPhos genes contributed to an increased risk of
type 2 diabetes or negatively influenced the quantitative
traits of insulin sensitivity and beta cell function.
However, in a very recent study [42], which was
published after the genotyping of OxPhos gene variants
in our Danish individuals [47], a gene set enrichment
analysis approach called MAGENTA was applied to
GWA data. The results show that the combined effects
of common genetic variants in transcriptional regulators
of mitochondrial genes, in OxPhos genes and in all other
known (~1,000) autosomal human mitochondrial genes
were not enriched for associations with type 2 diabetes or
related glycaemic traits. In the above-named study, the
statistical analysis was based on p values rather than
genotyping results, as the latter were not available [42].
Thus these data are consistent with our meta-analysis of
genotyping results from DIAGRAM+ [37] and the Danish
case–control cohort showing no robust association of
OxPhos gene variants with type 2 diabetes.
In summary, we report that among common variants
in or near OxPhos genes potentially contributing to type 2
diabetes susceptibility, minor alleles in the COX5B
and COX10 genes show only weak and nominally
significant associations with type 2 diabetes in a cohort
of Danish individuals. However, analysis of quantitative
metabolic traits in non-diabetic participants, and a large
meta-analysis of 11,729 cases and 43,943 controls
including our Danish cohort provide evidence that
common variation in proximity to OxPhos genes is not a
major cause of insulin resistance or common forms of type 2
diabetes.
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